Why the study?
Does low-dose trandolapril reduce atherosclerosis in Watanabe heritable hyperlipidemic rabbits?
Does low-dose trandolapril reduce atherosclerosis in Watanabe heritable hyperlipidemic rabbits?
The antiatherosclerotic effect of ACE inhibitors may not be directly related to arterial enzyme inhibition, as low-dose trandolapril suppressed ACE activity without reducing atherosclerosis in WHHL rabbits.
Answers are grounded in this paper and cite their sources.
Questions direct link between ACE inhibition and atherosclerosis reduction in hyperlipidemic models; leaves open alternative mechanisms or dosing effects.
This study was undertaken to determine whether low doses of the angiotensin-converting enzyme (ACE) inhibitor trandolapril affected atherosclerosis in the Watanabe heritable hyperlipidemic (WHHL) rabbit. Trandolapril (10 micrograms/kg body weight per 48 hours) was begun at 3 months of age and continued for 9 months. The selected dose reduced serum ACE activity but did not influence blood pressure. Both serum and aortic ACE activity were reduced by more than 80% in the trandolapril-treated compared with control WHHL rabbits, similar to the suppression achieved with the 25-fold-higher dose that in our previous studies induced marked inhibition of aortic atherosclerotic lesions in the WHHL rabbit. In contrast to these prior findings, low-dose trandolapril had no effect on aortic surface involvement by atherosclerosis, aortic cholesterol content, or aortic morphology. The data suggest that the antiatherosclerotic action of ACE inhibitors in the WHHL rabbit may not be related directly to arterial enzyme inhibition.
No takes yet. Share an insight, caveat, or question.
Chobanian et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: